NCT02676349 2026-03-27
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Phase 2 Completed
Institut de Cancérologie de Lorraine
Alliance for Clinical Trials in Oncology
Bayer
First Affiliated Hospital, Sun Yat-Sen University
Emory University
First Affiliated Hospital, Sun Yat-Sen University
Medical University of Silesia
Celgene
Institut Paoli-Calmettes
Indiana University
Karolinska Institutet
NYU Langone Health